Clinical trials
1 active trial in the US
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)
Updated
Reviewed by Vidhi Upadhyay
US Regenerative Aesthetics Market Industry Trends and Forecast to 2034: Segmented by (Treatment, Area, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$1.30 Bn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $988.9 Mn | — | — |
| 2025 (base) | $1.08 Bn | +$91.0 Mn | — |
| 2026 (forecast) | $1.18 Bn | +$99.4 Mn | +9.2% |
| 2027 (forecast) | $1.29 Bn | +$108.5 Mn | +19.2% |
| 2028 (forecast) | $1.41 Bn | +$118.5 Mn | +30.2% |
| 2029 (forecast) | $1.54 Bn | +$129.4 Mn | +42.2% |
| 2030 (forecast) | $1.68 Bn | +$141.3 Mn | +55.3% |
| 2031 (forecast) | $1.83 Bn | +$154.3 Mn | +69.6% |
| 2032 (forecast) | $2.00 Bn | +$168.5 Mn | +85.2% |
| 2033 (forecast) | $2.18 Bn | +$184.0 Mn | +102.2% |
| 2034 (forecast) | $2.38 Bn | +$200.9 Mn | +120.8% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $1.08 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.38 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 9.2% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Treatment, area and end user (see all) |
| Key players | Galderma S.A., Allergan, Merz Aesthetics, Croma Pharma, Benev (see all) |
| Active clinical trials | 1 in the USSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Regenerative aesthetics use treatments such as platelet-rich plasma, exosomes and biostimulators to repair and rejuvenate the skin.
Key segments of the regenerative Aesthetics market include treatment (Platelet-Rich Plasma, Biostimulatory Fillers and Exosome Therapy) and area (Face, Hair and Body).
An ageing population, longer life expectancy, rising interest in healthy ageing and new science on how the body ages are driving the regenerative Aesthetics market. Older adults and their families are spending more on staying active and independent.
Preventive care, personalised plans based on biomarkers and home-based services give the regenerative Aesthetics market room to grow, especially in fast-ageing countries in Asia and Europe.
Limited clinical proof for some longevity products, high out-of-pocket costs, regulation that does not treat ageing as a disease and uneven access hold back the regenerative Aesthetics market.
The regenerative Aesthetics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[1] ClinicalTrials.gov lists 1 study on Regenerative Aesthetics that is recruiting, active or about to start in the US.[2] People aged 65 and over: 18.4% of people in 2025, the latest World Bank figure for the US.[3]
[1] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
[2] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
Licensing, quality standards and payment models from public and private payers shape how regenerative Aesthetics services are delivered and paid for in US. Government health programs and insurance coverage are key to access.
What doctors and scientists are doing in Regenerative Aesthetics right now, from free public sources.
1 active trial in the US
Recruiting, about to start, or running now.
See every trial on ClinicalTrials.gov (opens in a new tab)18.4 % of people
People aged 65 and over, US, 2025 (World Bank).
Compare every country on the Public Health DashboardSources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 18 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, People aged 65 and over (% of people). Retrieved 18 Nov 2026.
[2] World Bank Open Data, Health spending per person (US$ per person). Retrieved 17 Nov 2026.
[3] World Bank Open Data, Doctors (per 1,000 people). Retrieved 18 Nov 2026.
From our blog
Pharmaceuticals · US
Medical Devices · US
Digital Health · US
Pharmaceuticals · US
Pharmaceuticals · US
Pharmaceuticals · US